{
    "P_NCT02872025": {
        "summary": "Sarah, a 42-year-old woman, has been diagnosed with high-grade ductal carcinoma in situ (DCIS) of the breast, which is hormone receptor-negative and HER2-positive. The tumor is approximately 6 cm in size. She has no history of other malignancies, autoimmune diseases, or prior use of tamoxifen or aromatase inhibitors. Her ECOG performance status is 0, indicating full activity. Sarah is considering participating in a clinical trial involving immunotherapy for high-risk DCIS.",
        "conditions": [
            "High-grade ductal carcinoma in situ",
            "HER2-positive breast cancer",
            "Hormone receptor-negative breast cancer",
            "Breast cancer",
            "Large tumor size",
            "No prior malignancies",
            "No autoimmune diseases",
            "No prior use of tamoxifen",
            "No prior use of aromatase inhibitors",
            "Normal organ function",
            "ECOG performance status 0",
            "Not pregnant",
            "Not breastfeeding",
            "Use of contraception",
            "No participation in other clinical trials recently",
            "No investigational treatments recently",
            "No known immunodeficiency",
            "No recent live vaccines",
            "Negative for hepatitis B",
            "Negative for hepatitis C",
            "No history of HIV",
            "Interest in clinical trials",
            "Potential immunotherapy treatment",
            "Intralesional injections",
            "mRNA-2752 treatment",
            "Immune checkpoint inhibitor",
            "Surgical removal of lesion",
            "Cancer immunotherapy",
            "Breast surgery",
            "Breast cancer research",
            "Clinical trials for breast cancer",
            "HER2 inhibitors"
        ]
    },
    "P_NCT03048942": {
        "summary": "Sophia, a 52-year-old woman, has been diagnosed with HER2-negative, ER-positive metastatic breast cancer. She has an ECOG performance status of 1 and no history of other malignancies. Her blood tests and liver function are within normal limits, and she has not received prior cytotoxic chemotherapy for metastatic disease. She is fit for cytotoxic chemotherapy and is considering clinical trials for treatment options.",
        "conditions": [
            "HER2-negative breast cancer",
            "Metastatic breast cancer",
            "ER-positive breast cancer",
            "Cytotoxic chemotherapy",
            "ECOG performance status 1",
            "No prior cytotoxic chemotherapy for metastatic disease",
            "No history of other malignancies",
            "Normal liver function",
            "Normal serum creatinine",
            "No symptomatic brain metastases",
            "Stable cardiovascular health",
            "No severe hypersensitivity to polysorbate 80-containing drugs",
            "No severe hypersensitivity to taxanes",
            "Not pregnant",
            "Not breastfeeding",
            "No contraindications to corticosteroid treatment",
            "No recent palliative radiotherapy",
            "No participation in clinical trials with investigational drugs in the past 30 days",
            "Hemoglobin level of 11.2 g/dL",
            "Absolute neutrophil count of 2.1 x 10^9/L",
            "Platelet count of 150 x 10^9/L",
            "Measurable disease according to RECIST 1.1 criteria",
            "Treatment-naive for metastatic disease",
            "Eligible for clinical trials",
            "Interested in clinical trial participation",
            "Cabazitaxel and paclitaxel chemotherapy",
            "Breast cancer chemotherapy",
            "HER2-negative cancer treatment",
            "ER-positive cancer treatment",
            "Metastatic cancer treatment",
            "Breast cancer clinical trials",
            "Chemotherapy clinical trials"
        ]
    },
    "P_NCT02448420": {
        "summary": "Emma, a 56-year-old postmenopausal woman, has HER2-positive, hormone receptor-positive metastatic breast cancer. She has undergone three lines of systemic treatment, including trastuzumab and chemotherapy, but her recent scans show progression in liver metastases. She has an ECOG performance status of 1, adequate organ function, and available tumor tissue for biomarker analysis. Emma has a history of cardiotoxicity but currently has no severe uncontrolled medical conditions. She is seeking clinical trials for new treatment options.",
        "conditions": [
            "HER2-positive metastatic breast cancer",
            "Hormone receptor-positive breast cancer",
            "Metastatic breast cancer",
            "Postmenopausal breast cancer",
            "Breast cancer with liver metastases",
            "Progression after trastuzumab",
            "ECOG performance status 1",
            "Adequate organ function",
            "Available tumor tissue for biomarker analysis",
            "History of cardiotoxicity",
            "Recovered cardiotoxicity",
            "No active infections",
            "No severe uncontrolled medical conditions",
            "Interested in clinical trials",
            "Previous chemotherapy treatment",
            "No history of other malignancies in the past five years",
            "No investigational drugs in the last two weeks",
            "Baseline left ventricular ejection fraction of 55%",
            "No signs of congestive heart failure",
            "No uncontrolled hypertension",
            "Breast cancer",
            "Cancer metastasis",
            "Systemic treatment for cancer",
            "Treatment-resistant cancer",
            "Advanced breast cancer",
            "HER2-positive cancer",
            "Hormone receptor-positive cancer",
            "Postmenopausal woman",
            "Liver metastases",
            "Chemotherapy",
            "Trastuzumab treatment",
            "Cardiotoxicity"
        ]
    },
    "P_NCT03740893": {
        "summary": "Ava, a 48-year-old woman, has triple-negative breast cancer (TNBC) with residual disease after six cycles of neoadjuvant chemotherapy. She is in good health with no history of other malignancies, adequate organ function, and no significant cardiovascular or autoimmune disorders. Ava is post-menopausal and has recovered from the acute side effects of chemotherapy, experiencing only mild fatigue. She is considered suitable for further surgical treatment and clinical trial participation.",
        "conditions": [
            "Triple-negative breast cancer",
            "Chemotherapy-resistant breast cancer",
            "Residual breast cancer",
            "Post-menopausal",
            "ECOG performance status 1",
            "Adequate hematological function",
            "Adequate renal function",
            "Adequate hepatic function",
            "No significant cardiovascular issues",
            "No autoimmune disorders",
            "No recent major surgeries",
            "No history of malignancies in the past five years",
            "Suitable for surgery",
            "Suitable for clinical trial participation",
            "DNA damage response inhibitors",
            "Anti-PD-L1 immunotherapy",
            "Phase IIa clinical trials",
            "Breast cancer surgery",
            "Curative intent surgery",
            "Chemotherapy-induced menopause",
            "No strong CYP3A inhibitors or inducers",
            "Recovered from chemotherapy side effects",
            "Grade 1 fatigue",
            "Pre-treatment biopsies",
            "Post-treatment biopsies",
            "Clinical trial eligibility",
            "Breast MRI findings",
            "Tumor focus measurement",
            "Chemotherapy cycles",
            "Neoadjuvant chemotherapy",
            "Immunotherapy",
            "Cancer treatment"
        ]
    },
    "P_NCT03315364": {
        "summary": "Olivia, a 54-year-old woman, has recurrent HER2-negative, hormone receptor-positive breast cancer with metastasis to the liver. She previously underwent surgery and radiation but has not received chemotherapy for her metastatic disease. Her last treatment with taxane was over 18 months ago. She has an ECOG performance status of 1 and experiences mild fatigue, with no neuropathy or central nervous system metastasis.",
        "conditions": [
            "Recurrent breast cancer",
            "HER2-negative breast cancer",
            "Hormone receptor-positive breast cancer",
            "Metastatic breast cancer",
            "Liver metastasis",
            "Breast cancer with liver involvement",
            "Post-surgical breast cancer recurrence",
            "Radiation-treated breast cancer",
            "No prior chemotherapy for metastatic disease",
            "Previous taxane treatment",
            "ECOG performance status 1",
            "Mild fatigue in cancer patient",
            "Absence of neuropathy in cancer patient",
            "No central nervous system metastasis",
            "Eligibility for breast cancer clinical trials",
            "Treatment options for metastatic breast cancer",
            "HER2-negative hormone receptor-positive cancer",
            "Advanced breast cancer",
            "Systemic therapy for breast cancer",
            "Breast cancer in postmenopausal women",
            "Non-chemotherapy treated metastatic breast cancer",
            "Follow-up of breast cancer post-surgery and radiation",
            "Breast cancer recurrence with distant metastasis",
            "Management of recurrent breast cancer",
            "Therapeutic strategies for hormone receptor-positive breast cancer",
            "Breast cancer without central nervous system involvement",
            "Breast cancer patient with liver metastasis",
            "Breast cancer follow-up imaging findings",
            "Breast cancer biopsy findings",
            "Breast cancer treatment history",
            "Breast cancer performance status assessment",
            "Breast cancer fatigue management"
        ]
    },
    "P_NCT03428802": {
        "summary": "Isabella, a 58-year-old woman, has stage IV breast cancer with liver metastasis and a BRCA2 mutation. Despite previous chemotherapy and targeted therapy, her disease progressed. She has an ECOG performance status of 1, indicating some limitations in daily activities. Her recent lab results show normal liver function but slightly reduced blood counts. She has no history of autoimmune diseases or immunodeficiency disorders, and no brain metastases. She has not received prior immunotherapy.",
        "conditions": [
            "Stage IV breast cancer",
            "Breast cancer with liver metastasis",
            "BRCA2 mutation",
            "Advanced solid tumors",
            "Genomic instability",
            "Metastatic breast cancer",
            "Previously treated breast cancer",
            "ECOG performance status 1",
            "Chemotherapy",
            "Targeted therapy",
            "Pembrolizumab",
            "Immunotherapy",
            "Clinical trials",
            "Cancer metastasis",
            "Liver metastasis",
            "Neutrophil count",
            "Platelet count",
            "Hemoglobin level",
            "Liver function tests",
            "No autoimmune diseases",
            "No immunodeficiency disorders",
            "No brain metastases",
            "Contraception in clinical trials",
            "Recovery from chemotherapy",
            "Potential immune-related adverse events",
            "Regular follow-up in clinical trials",
            "Cancer treatment side effects",
            "Use of dual contraception",
            "Solid tumors",
            "Cancer genomic testing",
            "Cancer progression",
            "Treatment-resistant cancer"
        ]
    },
    "P_NCT02583828": {
        "summary": "Maria, a 72-year-old woman, has metastatic breast cancer that is estrogen receptor-positive. Her disease has progressed despite standard chemotherapy. She has measurable disease, an ECOG performance status of 1, and adequate organ function. Her metastases are limited to bones and lungs, with no brain involvement. Her medical team is considering hormone therapy combined with low-dose chemotherapy.",
        "conditions": [
            "Metastatic breast cancer",
            "Estrogen receptor-positive breast cancer",
            "Progressed after chemotherapy",
            "Measurable disease according to RECIST",
            "ECOG performance status 1",
            "Adequate bone marrow function",
            "Adequate liver function",
            "Adequate renal function",
            "Bone metastases",
            "Lung metastases",
            "No brain metastases",
            "No history of other malignancies",
            "No uncontrolled concurrent medical conditions",
            "Elderly patient with cancer",
            "Hormone therapy in breast cancer",
            "Low-dose chemotherapy",
            "Quality of life in cancer treatment",
            "Alternative cancer treatments",
            "Breast cancer in the elderly",
            "Therapeutic options for metastatic breast cancer",
            "Management of bone metastases in breast cancer",
            "Management of lung metastases in breast cancer",
            "Cancer treatment in patients with adequate organ function",
            "Treatment options for estrogen receptor-positive cancer",
            "Chemotherapy-resistant breast cancer",
            "Second-line treatment for breast cancer",
            "Combination therapy in breast cancer",
            "Palliative care in metastatic breast cancer",
            "Advanced breast cancer treatment strategies",
            "Breast cancer treatment with no brain involvement",
            "Breast cancer clinical trials",
            "Personalized treatment approaches in breast cancer"
        ]
    },
    "P_NCT02344472": {
        "summary": "Charlotte, a 62-year-old postmenopausal woman, has metastatic HER2-positive and hormone receptor-positive breast cancer with liver metastases. She has previously undergone one line of chemotherapy but has not received pertuzumab or CDK4/6 inhibitors. Her condition is characterized by measurable lesions, an ECOG performance status of 1, and normal organ function. She has no significant cardiac, hypertensive, or diabetic issues.",
        "conditions": [
            "Metastatic breast cancer",
            "HER2-positive breast cancer",
            "Hormone receptor-positive breast cancer",
            "Liver metastases",
            "Postmenopausal",
            "Previous chemotherapy",
            "Measurable lesions",
            "ECOG performance status 1",
            "Normal liver enzymes",
            "Normal bilirubin levels",
            "Normal creatinine levels",
            "QTcF interval 440 msec",
            "Resting heart rate 72 bpm",
            "No serious cardiac disease",
            "No uncontrolled hypertension",
            "No significant diabetic complications",
            "Non-pregnant",
            "Agreed to use non-hormonal contraception",
            "Eligible for clinical trials",
            "Breast cancer with liver involvement",
            "HER2 IHC 3+",
            "Left ventricular ejection fraction 55%",
            "RECIST v1.1 measurable lesions",
            "No history of pertuzumab treatment",
            "No CDK4/6 inhibitors treatment",
            "Potential for chemotherapy",
            "Potential for endocrine therapy",
            "Dual HER2-targeted therapy",
            "Effective organ function",
            "Breast cancer in postmenopausal women",
            "Potential for clinical trial participation",
            "Chemotherapy versus endocrine therapy comparison"
        ]
    },
    "P_NCT02187991": {
        "summary": "Amelia, a 45-year-old postmenopausal woman, has metastatic ER-positive, HER2-negative breast cancer with lytic bone metastases. She has undergone chemotherapy and has an ECOG performance status of 1. Her lab results show mild abnormalities in liver function and she has grade 1 peripheral neuropathy from previous treatments. She has no severe concurrent medical or psychiatric conditions, no history of brain metastases, and no issues affecting oral medication absorption.",
        "conditions": [
            "Metastatic breast cancer",
            "ER-positive breast cancer",
            "HER2-negative breast cancer",
            "Postmenopausal",
            "Lytic bone metastases",
            "Chemotherapy",
            "RECIST measurable lesions",
            "ECOG performance status 1",
            "Liver function test abnormalities",
            "Peripheral neuropathy",
            "Neutropenia",
            "Thrombocytopenia",
            "Anemia",
            "Creatinine clearance",
            "No brain metastases",
            "No gastrointestinal disease affecting medication absorption",
            "No sleep apnea",
            "No investigational drugs within 30 days",
            "No severe medical conditions",
            "No psychiatric conditions",
            "No HIV",
            "No hepatitis B",
            "No hepatitis C",
            "No ongoing steroid therapy",
            "Able to swallow oral medications",
            "Normal ECG",
            "Not pregnant",
            "Not breastfeeding",
            "No acute ischemia",
            "No conduction system abnormalities",
            "Last menstrual period over a year ago",
            "No signs of acute ischemia or conduction system abnormalities"
        ]
    },
    "P_NCT01785420": {
        "summary": "Evelyn, a 60-year-old woman, has been diagnosed with stage II HER2-positive breast cancer, with a 2.5 cm tumor and no lymph node involvement. Her heart function is normal, and she has no significant past medical history of cardiac, hypertension, or gastrointestinal disorders. She is considering a clinical trial involving preoperative trastuzumab for HER2-positive breast cancer.",
        "conditions": [
            "HER2-positive breast cancer",
            "Stage II breast cancer",
            "Breast cancer",
            "Cancer of breast",
            "HER2 overexpression",
            "T2 breast cancer",
            "N0 breast cancer",
            "Preoperative trastuzumab",
            "Trastuzumab",
            "Disease-free survival in breast cancer",
            "Post-menopausal breast cancer",
            "Breast cancer surgery",
            "Adjuvant therapy in breast cancer",
            "Breast cancer clinical trials",
            "HER2-positive cancer treatment",
            "Oncology clinical trials",
            "Cancer immunotherapy",
            "Targeted therapy for breast cancer",
            "Breast cancer chemotherapy",
            "Breast cancer in elderly",
            "Breast cancer without lymph node involvement",
            "Breast cancer hormone therapy",
            "Breast cancer targeted therapy",
            "Breast cancer monoclonal antibody therapy",
            "Breast cancer preoperative therapy",
            "Breast cancer adjuvant therapy",
            "Breast cancer neoadjuvant therapy",
            "Breast cancer patient care",
            "Breast cancer prognosis",
            "Breast cancer treatment options",
            "Breast cancer research",
            "Breast cancer therapy"
        ]
    },
    "P_NCT03324425": {
        "summary": "Abigail, a 74-year-old woman, has metastatic HER2-positive breast cancer with disease progression despite dual anti-HER2 therapy. The cancer has spread to her liver and lungs, causing increased fatigue and shortness of breath. She has measurable lesions, an ECOG performance status of 1, and adequate organ function. She has not undergone major surgery or radiation recently, and her cardiovascular health is stable with controlled hypertension.",
        "conditions": [
            "metastatic HER2-positive breast cancer",
            "disease progression on anti-HER2 therapy",
            "liver metastases",
            "lung metastases",
            "increased fatigue",
            "shortness of breath",
            "measurable lesions according to RECIST",
            "ECOG performance status 1",
            "adequate organ function",
            "no recent major surgery",
            "no recent radiation therapy",
            "post-menopausal",
            "controlled hypertension",
            "no CNS metastases",
            "no history of rhabdomyolysis",
            "no alcohol abuse",
            "no hypersensitivity to statins",
            "no other malignancies in the past two years",
            "not currently participating in other clinical trials",
            "no statin use in the past six months",
            "normal ANC levels",
            "normal platelet count",
            "normal hemoglobin levels",
            "normal creatinine levels",
            "normal bilirubin levels",
            "normal ALT levels",
            "normal AST levels",
            "normal alkaline phosphatase levels",
            "normal CPK levels",
            "left ventricular ejection fraction of 55%",
            "no significant cardiovascular issues",
            "well-controlled blood pressure"
        ]
    },
    "P_NCT03546686": {
        "summary": "Madison, a 51-year-old woman, has triple-negative breast cancer with residual disease post-taxane-based neoadjuvant chemotherapy. Her tumor is ER, PR, and HER2 negative, with no distant metastases. She is scheduled for a lumpectomy and is considering a clinical trial involving pre-operative cryoablation and immune checkpoint inhibition.",
        "conditions": [
            "Triple-negative breast cancer",
            "Residual breast cancer",
            "ER-negative breast cancer",
            "PR-negative breast cancer",
            "HER2-negative breast cancer",
            "Post-chemotherapy breast cancer",
            "Breast cancer suitable for cryoablation",
            "Breast cancer with no distant metastasis",
            "Breast cancer eligible for lumpectomy",
            "Breast cancer in women",
            "Taxane-based chemotherapy",
            "Neoadjuvant chemotherapy",
            "Cryoablation",
            "Immune checkpoint inhibitors",
            "Event Free Survival in breast cancer",
            "Pre-operative therapy for breast cancer",
            "ECOG performance status 0",
            "Normal white blood cell count",
            "Normal platelet count",
            "Normal liver function tests",
            "No history of autoimmune diseases",
            "No other malignancies in the past five years",
            "Non-pregnant and non-breastfeeding women in clinical trials",
            "Use of contraception in clinical trials",
            "No recent live vaccines",
            "Not on chronic immunosuppressants",
            "Not on systemic corticosteroids",
            "Breast cancer clinical trials",
            "Cancer immunotherapy",
            "Surgical oncology",
            "Oncology clinical trials",
            "Women's health in oncology"
        ]
    },
    "P_NCT03025035": {
        "summary": "Emily, a 45-year-old woman, has advanced triple-negative breast cancer with a BRCA1 mutation. Her disease has progressed despite initial positive response to first-line chemotherapy. She has a measurable liver lesion, is postmenopausal, and has no history of other malignancies or autoimmune diseases. Her organ function is normal, and she has no infections like HIV or Hepatitis. Emily is interested in exploring treatment options involving pembrolizumab and olaparib.",
        "conditions": [
            "Advanced triple-negative breast cancer",
            "BRCA1 mutation",
            "Progressed after first-line chemotherapy",
            "Measurable disease by RECIST 1.1",
            "Liver metastasis",
            "ECOG performance status 1",
            "No brain metastases",
            "Postmenopausal",
            "No history of autoimmune diseases",
            "Normal organ function",
            "No history of other malignancies",
            "No history of HIV",
            "No history of Hepatitis B",
            "No history of Hepatitis C",
            "Has FFPE tumor tissue sample",
            "Not on strong CYP3A inhibitors or inducers",
            "Interested in pembrolizumab and olaparib treatment",
            "Chemotherapy-induced menopause",
            "Recovered from last chemotherapy",
            "No participation in other clinical trials",
            "No plans for pregnancy",
            "Breast cancer",
            "Cancer treatment",
            "Genetic mutation",
            "Oncology",
            "Targeted therapy",
            "Immunotherapy",
            "PARP inhibitors",
            "PD-1 inhibitors",
            "Chemotherapy",
            "Cancer progression",
            "Treatment-resistant cancer"
        ]
    },
    "P_NCT02095184": {
        "summary": "Scarlett, a 62-year-old postmenopausal woman, has been diagnosed with stage II, estrogen receptor-positive, HER2-negative breast cancer. The tumor is operable, measuring 2.5 cm, and she has no prior history of cancer treatments. She is obese with a BMI of 31 kg/m2 and has an ECOG performance status of 1. Her liver function and creatinine clearance are within normal limits. She has no allergies to anastrozole or letrozole, and her oncologist is considering neoadjuvant endocrine therapy with aromatase inhibitors.",
        "conditions": [
            "Breast cancer",
            "Stage II breast cancer",
            "Estrogen receptor-positive breast cancer",
            "HER2-negative breast cancer",
            "Postmenopausal breast cancer",
            "Operable breast cancer",
            "Obesity",
            "ECOG performance status 1",
            "No prior chemotherapy",
            "No prior radiation therapy",
            "No prior endocrine therapy",
            "Normal liver function",
            "Creatinine clearance",
            "No known allergies to anastrozole",
            "No known allergies to letrozole",
            "Neoadjuvant therapy",
            "Endocrine therapy",
            "Aromatase inhibitors",
            "Allred score 7",
            "Tumor size 2.5 cm",
            "Core needle biopsy",
            "Correlative studies",
            "Postmenopausal",
            "Ambulatory patient",
            "Light work capability",
            "No other malignancies in past 3 years",
            "Normal total bilirubin",
            "Normal AST",
            "Normal ALT",
            "BMI 31 kg/m2",
            "Anastrozole treatment",
            "Letrozole treatment"
        ]
    },
    "P_NCT02760030": {
        "summary": "Margaret, an 82-year-old woman, has been diagnosed with invasive breast cancer that is estrogen receptor-positive and HER2-negative. She is classified as frail with multiple co-morbidities and requires assistance with daily activities. She also has mild cognitive impairment and abnormal lab results including low neutrophils and platelets, and elevated liver enzymes. Margaret is seeking non-surgical treatment options.",
        "conditions": [
            "Invasive breast cancer",
            "Estrogen receptor-positive breast cancer",
            "HER2-negative breast cancer",
            "Frailty",
            "Geriatric syndrome",
            "Mild cognitive impairment",
            "Neutropenia",
            "Thrombocytopenia",
            "Elevated liver enzymes",
            "Breast cancer in the elderly",
            "Non-surgical breast cancer treatment",
            "Breast cancer clinical trials",
            "Geriatric oncology",
            "Breast cancer hormone therapy",
            "Activities of daily living dependency",
            "Comorbidities in the elderly",
            "Liver function test abnormalities",
            "Breast cancer without prior aromatase inhibitor therapy",
            "Breast cancer without distant metastases",
            "CYP3A4 interactions",
            "Breast cancer treatment in frail patients",
            "Avoidance of surgery in breast cancer treatment",
            "Breast cancer therapy options",
            "Geriatric assessment in cancer",
            "Breast cancer personalized treatment",
            "Breast cancer management in cognitive impairment",
            "Breast cancer prognosis in the elderly",
            "Breast cancer decision making",
            "Breast cancer supportive care",
            "Breast cancer palliative care",
            "Breast cancer and liver enzyme elevation",
            "Breast cancer and hematological parameters"
        ]
    },
    "P_NCT03500380": {
        "summary": "Victoria, a 68-year-old postmenopausal woman, has HER2-positive metastatic breast cancer with liver metastases. She has undergone previous treatments including trastuzumab and two lines of chemotherapy, with the most recent being a taxane-based regimen. Despite these treatments, her cancer has progressed. She has good overall health with an ECOG performance status of 1 and no major health issues outside of her cancer.",
        "conditions": [
            "HER2-positive metastatic breast cancer",
            "Liver metastases",
            "Postmenopausal",
            "Disease progression after chemotherapy",
            "Previous treatment with trastuzumab",
            "Previous taxane-based chemotherapy",
            "ECOG performance status 1",
            "Adequate bone marrow function",
            "Adequate liver function",
            "Adequate renal function",
            "No history of cardiovascular issues",
            "Normal left ventricular ejection fraction",
            "No investigational drugs recently",
            "No major surgeries recently",
            "No known medication hypersensitivity",
            "No uncontrolled systemic diseases",
            "No history of other malignancies",
            "Negative for HIV",
            "Negative for active hepatitis",
            "No recent thromboembolic events",
            "No prior capecitabine treatment",
            "No prior exposure to HER2 tyrosine kinase inhibitors",
            "No prior exposure to T-DM1",
            "Measurable lesion according to RECIST v1.1",
            "Breast cancer",
            "Cancer relapse",
            "Cancer metastasis",
            "Chemotherapy",
            "Trastuzumab treatment history",
            "Taxane treatment history",
            "Metastatic cancer",
            "Oncology"
        ]
    },
    "P_NCT03515798": {
        "summary": "Aria, a 59-year-old woman, has been diagnosed with inflammatory breast cancer, which is HER2-negative and has known hormone receptor status. She exhibits symptoms such as erythema, edema, and peau d'orange appearance, with no evidence of metastatic disease. Her overall health is good, with normal organ function and an ECOG performance status of 1. She has no history of autoimmune diseases, immunodeficiency, or use of immunosuppressive medications, and has not received any prior treatment for her breast cancer.",
        "conditions": [
            "Inflammatory breast cancer",
            "HER2-negative breast cancer",
            "Hormone receptor positive breast cancer",
            "Non-metastatic breast cancer",
            "Breast cancer",
            "Erythema in breast cancer",
            "Edema in breast cancer",
            "Peau d'orange appearance in breast cancer",
            "ECOG performance status 1",
            "Adequate organ function",
            "Normal hematologic function",
            "Normal liver function",
            "Normal kidney function",
            "No history of autoimmune diseases",
            "No immunodeficiency",
            "No recent use of immunosuppressive medications",
            "No prior breast cancer treatment",
            "No history of other malignancies",
            "Not pregnant",
            "Not breastfeeding",
            "Use of contraception",
            "No allergies to pembrolizumab",
            "No participation in other clinical trials",
            "No recent live vaccines",
            "Negative for HIV",
            "Negative for active hepatitis B",
            "Negative for active hepatitis C",
            "No history of pneumonitis",
            "No active infections requiring systemic therapy",
            "Female",
            "Age 59",
            "Good overall health"
        ]
    },
    "P_NCT03272334": {
        "summary": "Grace, a 55-year-old woman, has metastatic breast cancer that is HER2-negative and has progressed despite multiple treatments including chemotherapy and hormonal therapy. She has metastatic lesions in her liver and lungs, and her ECOG performance status is 1. She has normal organ function and no history of autoimmune diseases, recent infections, or cardiac issues. She is post-menopausal, not pregnant, and has not received immunotherapy previously.",
        "conditions": [
            "Metastatic breast cancer",
            "HER2-negative breast cancer",
            "Progressive breast cancer",
            "Metastatic lesions in liver",
            "Metastatic lesions in lungs",
            "ECOG performance status 1",
            "Post-menopausal",
            "Normal organ function",
            "No history of autoimmune diseases",
            "No recent infections",
            "No known cardiac issues",
            "No prior immunotherapy",
            "Completed chemotherapy",
            "Breast cancer with liver involvement",
            "Breast cancer with lung involvement",
            "Chemotherapy-resistant breast cancer",
            "Hormonal therapy-resistant breast cancer",
            "Eligible for clinical trials",
            "Novel therapies for breast cancer",
            "Combination therapy for breast cancer",
            "Advanced breast cancer",
            "Systemic therapy for breast cancer",
            "Targeted therapy for breast cancer",
            "Therapeutic options for metastatic breast cancer",
            "Breast cancer treatment options",
            "Breast cancer clinical trials",
            "Non-pregnant",
            "Adult female cancer patient",
            "Breast cancer in post-menopausal women",
            "Breast cancer with measurable disease",
            "Breast cancer with multiple treatment lines",
            "Breast cancer with organ involvement"
        ]
    },
    "P_NCT02977468": {
        "summary": "Chloe, a 45-year-old woman, has been diagnosed with triple-negative breast cancer with a 2.5 cm tumor in her left breast, no lymph node involvement or metastatic disease. She has not undergone any prior cancer treatments and has good overall health with an ECOG performance status of 0. She has no significant medical history that would interfere with clinical trial participation.",
        "conditions": [
            "Triple-negative breast cancer",
            "Breast cancer",
            "Cancer of the breast",
            "No prior cancer treatment",
            "ECOG performance status 0",
            "Adequate organ function",
            "No autoimmune disorders",
            "No immunodeficiency",
            "Effective contraception",
            "No allergies to pembrolizumab",
            "No history of pneumonitis",
            "No active infections",
            "No other malignancies in the past five years",
            "No psychiatric disorders",
            "No substance abuse disorders",
            "No prior immunotherapy",
            "Negative for Hepatitis B",
            "Negative for Hepatitis C",
            "No live vaccines in the past 30 days",
            "No history of organ transplants",
            "No allogeneic stem cell transplants",
            "No lymph node involvement",
            "No metastatic disease",
            "No history of cancer treatment",
            "No prior chemotherapy",
            "No prior radiation therapy",
            "No prior surgery for cancer",
            "No known drug allergies",
            "No history of infectious diseases",
            "No genetic disorders",
            "No hormonal disorders",
            "Good overall health"
        ]
    },
    "P_NCT02627248": {
        "summary": "Lily, a 72-year-old woman, has been diagnosed with stage III ductal carcinoma of the breast, measuring 3.5 cm. She is set to undergo neoadjuvant chemotherapy to reduce tumor size before surgery. Her medical history is clear of significant comorbidities, and her liver and kidney functions are normal. She is not pregnant, lactating, nor does she have HIV/AIDS or other severe diseases. Her oncologist is considering including her in a clinical trial for neoadjuvant chemotherapy combined with Huaier Granule.",
        "conditions": [
            "Locally advanced breast cancer",
            "Stage III ductal carcinoma",
            "Breast cancer",
            "Neoadjuvant chemotherapy",
            "Elderly patients with cancer",
            "Cancer chemotherapy",
            "Breast neoplasms",
            "Tumor size greater than 3 cm",
            "No significant comorbidities",
            "Normal liver function",
            "Normal kidney function",
            "Non-pregnant",
            "Non-lactating",
            "No HIV or AIDS",
            "Good overall health",
            "Expected survival time more than 8 months",
            "Huaier Granule treatment",
            "Traditional Chinese medicine in cancer treatment",
            "Chemotherapy effectiveness",
            "Cancer treatment in elderly",
            "Oncology clinical trials",
            "Therapeutic oncology",
            "Cancer staging",
            "Cancer patient management",
            "Clinical trial participation",
            "Treatment options for breast cancer",
            "Cancer tumor reduction strategies",
            "Chemotherapy side effects",
            "Cancer survival rates",
            "Cancer patient quality of life",
            "Research in cancer therapies",
            "Advanced cancer treatments"
        ]
    },
    "P_NCT03747120": {
        "summary": "Aubrey, a 67-year-old woman, has been diagnosed with invasive HER2-positive breast cancer, staged as cT2N1M0, indicating a primary tumor of 3.5 cm and clinically suspicious lymph nodes but no metastasis. She has not undergone any prior treatment for breast cancer and maintains good overall health with an ECOG performance status of 1. Her organ functions are normal, and she has no history of other significant health issues. Aubrey is not pregnant, agrees to use contraception, and has consented to participate in clinical trials.",
        "conditions": [
            "HER2-positive breast cancer",
            "Invasive breast cancer",
            "Non-metastatic breast cancer",
            "cT2N1M0 breast cancer",
            "Breast cancer with suspicious lymph nodes",
            "Breast cancer in females",
            "ECOG performance status 1",
            "Adequate organ function",
            "Normal liver function",
            "Normal renal function",
            "Normal blood counts",
            "Left ventricular ejection fraction 58%",
            "No history of autoimmune diseases",
            "No history of immunodeficiency",
            "No history of other malignancies",
            "Not pregnant",
            "Willing to use effective contraception",
            "No recent investigational agents",
            "No recent live vaccines",
            "No significant cardiovascular disease",
            "Not on immunosuppressive medications",
            "Willing to provide tumor tissue samples",
            "Eligible for clinical trials",
            "Breast cancer stage II",
            "Breast cancer with lymph node involvement",
            "Postmenopausal breast cancer",
            "Senior patient with breast cancer",
            "Breast cancer initial treatment",
            "Breast cancer chemotherapy",
            "Targeted therapy for breast cancer",
            "Breast cancer hormonal status",
            "Breast cancer research participant"
        ]
    },
    "P_NCT02926690": {
        "summary": "Natalie, a 72-year-old woman, has locally advanced triple-negative breast cancer (TNBC) with metastases to her liver. Despite initial treatments including anthracyclines, taxanes, surgery, radiation, and a platinum-based regimen, her disease has progressed. She is now being considered for a Phase I clinical trial for a new drug, OTS167PO, a MELK inhibitor. Her hormone receptor status is ER <10%, PR <10%, and HER2 negative. Natalie has an ECOG performance status of 1, adequate organ function, and no significant comorbidities.",
        "conditions": [
            "Triple-negative breast cancer",
            "Metastatic breast cancer",
            "Liver metastases",
            "Advanced breast cancer",
            "Breast cancer resistant to anthracyclines",
            "Breast cancer resistant to taxanes",
            "Breast cancer resistant to platinum-based therapy",
            "ER-negative breast cancer",
            "PR-negative breast cancer",
            "HER2-negative breast cancer",
            "ECOG performance status 1",
            "Eligibility for clinical trials",
            "Potential for biopsy of liver lesions",
            "Adequate liver function",
            "Adequate renal function",
            "Adequate hematologic status",
            "No active infections",
            "No cardiovascular disease",
            "No history of HIV",
            "No active hepatitis",
            "No hypersensitivity to OTS167",
            "No recent anti-neoplastic agents",
            "No recent radiotherapy",
            "Life expectancy greater than 3 months",
            "MELK inhibitor as a treatment",
            "Phase I clinical trials",
            "Cancer progression after multiple lines of therapy",
            "Need for new therapeutic options",
            "Breast cancer in elderly",
            "Breast cancer with measurable lesions",
            "Breast cancer with liver involvement",
            "Breast cancer with potential for targeted therapy"
        ]
    },
    "P_NCT02716116": {
        "summary": "Hannah, a 52-year-old woman, has stage IV non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation. She has undergone first-line chemotherapy and treatment with an EGFR tyrosine kinase inhibitor, both of which initially showed partial response or no objective response, respectively. Her disease has progressed with lesions in her lungs and liver. She has an ECOG performance status of 1, maintained adequate organ function, and no CNS metastases.",
        "conditions": [
            "Stage IV non-small cell lung cancer",
            "NSCLC with EGFR exon 20 insertion mutation",
            "Metastatic non-small cell lung cancer",
            "Progressive non-small cell lung cancer",
            "EGFR exon 20 insertion mutation",
            "Treatment-resistant non-small cell lung cancer",
            "Lung and liver metastases",
            "Failed response to first-line chemotherapy",
            "Failed response to EGFR tyrosine kinase inhibitor",
            "ECOG performance status 1",
            "Adequate organ function",
            "No CNS metastases",
            "No prior radiotherapy in the last month",
            "No use of strong CYP3A inhibitors or inducers",
            "Interest in new treatment options",
            "Quality of life improvement",
            "Disease control",
            "Advanced lung cancer",
            "Lung cancer with liver metastases",
            "Chemotherapy partial response",
            "Non-responder to EGFR TKI therapy",
            "Eligibility for clinical trials",
            "Exploratory treatments for lung cancer",
            "Second-line therapy for NSCLC",
            "Third-line therapy options for NSCLC",
            "Targeted therapy for NSCLC",
            "Experimental treatments for lung cancer",
            "Clinical trials for EGFR mutated NSCLC",
            "Advanced therapy options for NSCLC",
            "Therapeutic resistance in lung cancer",
            "Liver metastases from lung cancer",
            "Comprehensive genomic profiling of lung cancer"
        ]
    },
    "P_NCT01817452": {
        "summary": "Lillian, a 48-year-old woman, has been diagnosed with unilateral primary invasive carcinoma of the breast, classified as T2N1M0, HER2-positive, and hormone receptor-negative (ER-negative and PR-negative). She has no history of other malignancies or significant comorbidities, and her cardiac function is normal. She has not received any prior treatment for her breast cancer and is interested in neoadjuvant therapy options, particularly in clinical trials for targeted therapies.",
        "conditions": [
            "HER2-positive breast cancer",
            "Invasive ductal carcinoma",
            "Stage II breast cancer",
            "Node-positive breast cancer",
            "Hormone receptor-negative breast cancer",
            "ER-negative breast cancer",
            "PR-negative breast cancer",
            "Breast cancer T2N1M0",
            "No prior breast cancer treatment",
            "Interested in neoadjuvant therapy",
            "Eligible for clinical trials",
            "No history of malignancies",
            "Normal cardiac function",
            "Normal left ventricular ejection fraction",
            "ECOG performance status 1",
            "No known hypersensitivity to trastuzumab",
            "No known hypersensitivity to pertuzumab",
            "No known hypersensitivity to paclitaxel",
            "Not pregnant",
            "Not breastfeeding",
            "Using non-hormonal contraception",
            "Primary invasive breast cancer",
            "Unilateral breast cancer",
            "No distant metastasis",
            "No significant comorbidities",
            "Good overall health",
            "Interested in targeted therapies",
            "HER2-positive cancer",
            "Breast carcinoma",
            "Female breast cancer",
            "Adult female cancer patient",
            "Potential for neoadjuvant therapy participation"
        ]
    },
    "P_NCT03596073": {
        "summary": "Addison, a 58-year-old postmenopausal woman, has been diagnosed with stage I hormone receptor-positive invasive ductal carcinoma in her left breast. The tumor measures 1.5 cm and she has no history of breast cancer in the past 5 years. She is in good overall health with no history of immunosuppression, hypercalcemia, or vitamin D toxicity. Addison has not undergone recent chemotherapy or radiotherapy and is not involved in other clinical trials. She is considering participating in a research study on the use of topical calcipotriene ointment for breast cancer immunoprevention, which involves applying the ointment or a placebo between biopsy and surgical tumor removal.",
        "conditions": [
            "Stage I breast cancer",
            "Invasive ductal carcinoma",
            "Hormone receptor-positive breast cancer",
            "Postmenopausal woman",
            "Breast cancer immunoprevention",
            "Topical calcipotriene",
            "No history of breast cancer in the past 5 years",
            "No neoadjuvant therapy",
            "Good overall health",
            "No history of immunosuppression",
            "No hypercalcemia",
            "No vitamin D toxicity",
            "No recent chemotherapy",
            "No recent radiotherapy",
            "Not participating in other clinical trials",
            "Surgical tumor removal",
            "Core biopsy",
            "Randomized controlled trial",
            "Placebo-controlled study",
            "Immune cell infiltration",
            "Tumor microenvironment",
            "Treatment-related adverse events",
            "Breast lesion",
            "Cancer immunotherapy",
            "Oncology clinical trials",
            "Breast cancer treatment",
            "Breast cancer surgery",
            "Breast cancer research",
            "Cancer prevention",
            "Cancer immunology",
            "Clinical trial participation",
            "Breast health"
        ]
    },
    "P_NCT02965950": {
        "summary": "Eleanor, a 53-year-old woman, has locally advanced, triple-negative breast cancer that is resistant to taxanes and anthracyclines and harbors a TP53 mutation. Her cancer has not responded well to initial treatments and shows measurable disease in her breast and axillary lymph nodes. She is in good overall health with a WHO performance status of 0 and normal organ function. Her oncologist is considering clinical trials for alternative treatments, specifically targeting her TP53 mutation with dose-dense cyclophosphamide.",
        "conditions": [
            "Triple-negative breast cancer",
            "TP53 mutation",
            "Locally advanced breast cancer",
            "Breast cancer resistant to taxanes",
            "Breast cancer resistant to anthracyclines",
            "Measurable disease in breast",
            "Measurable disease in axillary lymph nodes",
            "Good overall health",
            "WHO performance status 0",
            "Normal neutrophil count",
            "Normal platelet count",
            "Normal liver function",
            "Normal kidney function",
            "No history of serious coagulopathy",
            "No active infections",
            "Not pregnant",
            "Not lactating",
            "No known hypersensitivity to cyclophosphamide",
            "No known hypersensitivity to pegfilgrastim",
            "Primary tumor accessible for biopsy",
            "Exploring alternative treatment options",
            "Potential clinical trial participant",
            "Dose-dense cyclophosphamide treatment",
            "Breast cancer",
            "Cancer treatment resistance",
            "Estrogen receptor negative",
            "Progesterone receptor negative",
            "HER2 negative",
            "Advanced breast cancer",
            "Breast cancer with axillary involvement",
            "Breast cancer with genetic mutation",
            "Breast cancer with measurable disease"
        ]
    },
    "P_NCT02632448": {
        "summary": "Stella, a 48-year-old woman, has advanced triple-negative breast cancer with liver metastases. Despite undergoing two rounds of chemotherapy, her cancer has progressed. She is being considered for a clinical trial involving LY2880070 and gemcitabine for advanced solid tumors. Stella has an ECOG performance status of 1, a life expectancy over 12 weeks, and normal organ function. She meets the criteria for measurable tumor lesions and has no CNS metastases, other active cancers, or recent investigational drug use.",
        "conditions": [
            "Triple-negative breast cancer",
            "Metastatic breast cancer",
            "Advanced solid tumors",
            "Liver metastases",
            "Chemotherapy-resistant cancer",
            "ECOG performance status 1",
            "Measurable tumor lesions",
            "No central nervous system metastases",
            "Normal organ function",
            "Not pregnant or nursing",
            "No other active cancers",
            "Normal QTcB interval",
            "Eligibility for clinical trials",
            "Life expectancy more than 12 weeks",
            "RECIST v1.1 criteria",
            "Cancer progression after chemotherapy",
            "Potential clinical trial participant",
            "Advanced cancer treatment",
            "Investigational drug therapy",
            "Gemcitabine treatment",
            "LY2880070 treatment",
            "Oral and intravenous chemotherapy",
            "21-day treatment cycles",
            "Safety and efficacy evaluation",
            "Cancer drug combination therapy",
            "No recent investigational drugs",
            "Breast cancer in women",
            "Adult cancer patients",
            "Metastatic disease management",
            "Therapeutic drug monitoring",
            "Clinical oncology research",
            "Targeted therapy for breast cancer"
        ]
    },
    "P_NCT02615457": {
        "summary": "Nora, a 65-year-old woman, was recently diagnosed with triple negative breast cancer and underwent surgery to remove the tumor. Post-surgery, her liver and kidney function tests were normal. She has no history of severe acute or chronic diseases, diabetes, or serious infectious diseases, and she is not pregnant or lactating. Her overall health is good, with no active bleeding, HIV, or AIDS-associated diseases.",
        "conditions": [
            "Triple negative breast cancer",
            "Breast cancer",
            "Post-surgical recovery",
            "Cancer surgery",
            "Liver function normal",
            "Kidney function normal",
            "Elderly patient with cancer",
            "No preoperative anticancer drugs",
            "Normal hemoglobin levels",
            "Normal platelet count",
            "Normal neutrophil count",
            "No history of diabetes",
            "No serious infectious diseases",
            "Non-pregnant",
            "Non-lactating",
            "Good oral medication tolerance",
            "No active bleeding",
            "No HIV or AIDS",
            "No history of drug abuse",
            "No psychological or mental health issues",
            "Cancer in elderly",
            "Postoperative cancer patient",
            "Cancer patient with normal liver function",
            "Cancer patient with normal kidney function",
            "Cancer patient with normal blood counts",
            "No chronic diseases",
            "No acute diseases",
            "Eligible for clinical trials",
            "Potential for long-term survival",
            "No contraindications for clinical trials",
            "Suitable for new cancer therapies",
            "Eligible for cancer research studies"
        ]
    },
    "P_NCT03090165": {
        "summary": "Lucy, a 74-year-old woman, has metastatic triple-negative breast cancer (TNBC) that is androgen receptor (AR) positive. Despite undergoing two lines of systemic therapy, her cancer has progressed. She has an ECOG performance status of 1, measurable disease, and adequate organ function. She is eligible for a clinical trial involving ribociclib and bicalutamide targeting AR+ TNBC.",
        "conditions": [
            "Metastatic triple-negative breast cancer",
            "Androgen receptor positive breast cancer",
            "Progressive metastatic breast cancer",
            "Eligibility for ribociclib and bicalutamide treatment",
            "ECOG performance status 1",
            "Measurable disease according to RECIST 1.1",
            "Adequate bone marrow function",
            "Adequate organ function",
            "No central nervous system metastases",
            "No history of cardiovascular disease",
            "No prior therapy with androgen receptor antagonists",
            "No prior therapy with CDK 4/6 inhibitors",
            "Not pregnant",
            "No other active malignancies",
            "No medications that prolong QT interval",
            "No strong inducers/inhibitors of CYP3A4/5",
            "QTc of 440ms",
            "Resting heart rate of 72 bpm",
            "Completed last cancer treatment six weeks ago",
            "No significant medical conditions contraindicating study participation",
            "Breast cancer",
            "Cancer systemic therapy",
            "Advanced breast cancer",
            "Cancer clinical trials",
            "CDK 4/6 inhibitor therapy",
            "Androgen receptor inhibitor therapy",
            "Eligibility for clinical trials",
            "Breast cancer treatment",
            "Systemic therapy for breast cancer",
            "Clinical trial participation",
            "Cancer progression",
            "Cancer treatment eligibility"
        ]
    },
    "P_NCT03685331": {
        "summary": "Mia, a 54-year-old woman, has metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer with liver metastases and a germline BRCA2 mutation. Her cancer is progressing despite one line of chemotherapy completed 4 months ago. She has an ECOG performance status of 1, has undergone natural menopause, and has no other significant health issues. Mia has not been treated with olaparib or palbociclib and has adequate organ and bone marrow function.",
        "conditions": [
            "Metastatic breast cancer",
            "Estrogen receptor-positive (ER+) breast cancer",
            "HER2-negative breast cancer",
            "Liver metastases",
            "Germline BRCA2 mutation",
            "Progressing cancer after chemotherapy",
            "Previous chemotherapy treatment",
            "ECOG performance status 1",
            "Post-menopausal",
            "Adequate organ function",
            "Adequate bone marrow function",
            "No prior treatment with olaparib",
            "No prior treatment with palbociclib",
            "No brain metastases",
            "Ability to swallow oral medications",
            "Not pregnant",
            "Willing to use effective contraception",
            "Breast cancer with liver involvement",
            "Cancer treatment options",
            "Eligibility for clinical trials",
            "Breast cancer genetic mutations",
            "Systemic therapy for breast cancer",
            "Targeted therapy for breast cancer",
            "Hormone receptor-positive cancer treatment",
            "Advanced breast cancer",
            "Therapeutic resistance in breast cancer",
            "Breast cancer in postmenopausal women",
            "Breast cancer chemotherapy",
            "Clinical trial eligibility",
            "Breast cancer progression",
            "Treatment-naive for specific drugs",
            "Patient willing for clinical trial participation"
        ]
    }
}